19 research outputs found

    Single cell transcript profiling of dormant myeloma cells identifies therapeutic and prognostic targets

    Full text link
    Multiple myeloma is a neoplasm of plasma cells which develops in the skeleton. The bone microenvironment supports myeloma growth and long-term survival of dormant myeloma cells. Despite targeted treatments, patients relapse and survival is poor. Dormant cells contribute to disease relapse and represent potential therapeutic targets. However, the molecular pathways that control dormancy are unclear. We developed a method to identify dormant cells in vivo and have used both microarray and single cell RNA sequencing (scRNA-seq) approaches to define the transcriptome profile of these cells. To identify dormant myeloma cells in the skeleton, 5TGM1 murine myeloma cells expressing eGFP were labelled with a fluorescent membrane dye, (Vybrant DiD). Dividing cells share DiD with daughter cells which DiD is diluted and activated cells become DiDneg, whereas, non-dividing dormant cells retain DiD (DiDhigh). DiD-labelled cells were injected (i.v.) into C57BLKalwRij mice. After 21 days, individual DiDhigh and DiDneg cells were sorted into 384 well plates by FACS for scRNA-seq and sequenced at >2x10^6 reads/cell. 5TGM1 cells were validated by the reconstruction of the unique clonal idiotypic sequence and the expression of specific Ig genes. A mean of ~4000 unique transcripts were identified with over 900 genes up-regulated in DiDhigh cells compared to DiDneg cells (fold change >2). Functional annotation of differentially expressed genes confirmed the dormant status of DiDhigh cells with down-regulation of metabolic pathways and up-regulation of immune system-related pathways. We identified the receptor tyrosine kinase, Axl, as a potential therapeutic target. FACS analysis confirmed expression in dormant cells and analysis of CD138+/CD38+ plasma cells from myeloma patients identified a small population of cells express AXL. Inhibition of Axl with Cabozantinib or BMS-777607 decreased dormant cell numbers and increased tumour burden in myeloma bearing mice suggesting Axl is functionally important in dormancy retention. Moreover, survival analysis in independent patient cohorts correlated the dormancy signature expressed in dormant myeloma cells with improved survival. These data demonstrate that dormant myeloma cells persist in the skeleton, have a unique transcript profile and this knowledge can be used to predict survival and identify new targets that alter the behaviour of myeloma disease in the skeleton

    Gene expression predicts dormant metastatic breast cancer cell phenotype

    Get PDF
    BACKGROUND: Breast cancer can recur months to decades after an initial diagnosis and treatment. The mechanisms that control tumor cell dormancy remain poorly understood, making it difficult to predict which patients will recur and thus benefit from more rigorous screening and treatments. Unfortunately, the extreme rarity of dormant DTCs has been a major obstacle to their study. METHODS: To overcome this challenge, we developed an efficient system to isolate and study rare dormant breast cancer cells from metastatic organs including bones, which represent a major site of metastasis. After isolation of cells from the long bones, we used single cell RNA-sequencing (scRNA-seq) to profile proliferative and dormant PyMT-Bo1 breast cancer cells. We also compared this signature to dormant versus proliferative tumor cells isolated from the lungs. Finally, we compared our dormant signature to human datasets. RESULTS: We identified a group of genes including Cfh, Gas6, Mme and Ogn that were highly expressed in dormant breast cancer cells present in the bone and lung. Expression of these genes had no impact on dormancy in murine models, but their expression correlated with disease-free survival in primary human breast cancer tumors, suggesting that these genes have predictive value in determining which patients are likely to recur. CONCLUSIONS: Dormant breast cancer cells exhibit a distinct gene expression signature regardless of metastatic site. Genes enriched in dormant breast cancer cells correlate with recurrence-free survival in breast cancer patients

    Prevalence, associated factors and outcomes of pressure injuries in adult intensive care unit patients: the DecubICUs study

    Get PDF
    Funder: European Society of Intensive Care Medicine; doi: http://dx.doi.org/10.13039/501100013347Funder: Flemish Society for Critical Care NursesAbstract: Purpose: Intensive care unit (ICU) patients are particularly susceptible to developing pressure injuries. Epidemiologic data is however unavailable. We aimed to provide an international picture of the extent of pressure injuries and factors associated with ICU-acquired pressure injuries in adult ICU patients. Methods: International 1-day point-prevalence study; follow-up for outcome assessment until hospital discharge (maximum 12 weeks). Factors associated with ICU-acquired pressure injury and hospital mortality were assessed by generalised linear mixed-effects regression analysis. Results: Data from 13,254 patients in 1117 ICUs (90 countries) revealed 6747 pressure injuries; 3997 (59.2%) were ICU-acquired. Overall prevalence was 26.6% (95% confidence interval [CI] 25.9–27.3). ICU-acquired prevalence was 16.2% (95% CI 15.6–16.8). Sacrum (37%) and heels (19.5%) were most affected. Factors independently associated with ICU-acquired pressure injuries were older age, male sex, being underweight, emergency surgery, higher Simplified Acute Physiology Score II, Braden score 3 days, comorbidities (chronic obstructive pulmonary disease, immunodeficiency), organ support (renal replacement, mechanical ventilation on ICU admission), and being in a low or lower-middle income-economy. Gradually increasing associations with mortality were identified for increasing severity of pressure injury: stage I (odds ratio [OR] 1.5; 95% CI 1.2–1.8), stage II (OR 1.6; 95% CI 1.4–1.9), and stage III or worse (OR 2.8; 95% CI 2.3–3.3). Conclusion: Pressure injuries are common in adult ICU patients. ICU-acquired pressure injuries are associated with mainly intrinsic factors and mortality. Optimal care standards, increased awareness, appropriate resource allocation, and further research into optimal prevention are pivotal to tackle this important patient safety threat

    DataSheet_1_High titre neutralizing antibodies in response to SARS–CoV–2 infection require RBD–specific CD4 T cells that include proliferative memory cells.pdf

    No full text
    BackgroundLong-term immunity to SARS-CoV-2 infection, including neutralizing antibodies and T cell-mediated immunity, is required in a very large majority of the population in order to reduce ongoing disease burden.MethodsWe have investigated the association between memory CD4 and CD8 T cells and levels of neutralizing antibodies in convalescent COVID-19 subjects.FindingsHigher titres of convalescent neutralizing antibodies were associated with significantly higher levels of RBD-specific CD4 T cells, including specific memory cells that proliferated vigorously in vitro. Conversely, up to half of convalescent individuals had low neutralizing antibody titres together with a lack of receptor binding domain (RBD)-specific memory CD4 T cells. These low antibody subjects had other, non-RBD, spike-specific CD4 T cells, but with more of an inhibitory Foxp3+ and CTLA-4+ cell phenotype, in contrast to the effector T-bet+, cytotoxic granzymes+ and perforin+ cells seen in RBD-specific memory CD4 T cells from high antibody subjects. Single cell transcriptomics of antigen-specific CD4+ T cells from high antibody subjects similarly revealed heterogenous RBD-specific CD4+ T cells that comprised central memory, transitional memory and Tregs, as well as cytotoxic clusters containing diverse TCR repertoires, in individuals with high antibody levels. However, vaccination of low antibody convalescent individuals led to a slight but significant improvement in RBD-specific memory CD4 T cells and increased neutralizing antibody titres.InterpretationOur results suggest that targeting CD4 T cell epitopes proximal to and within the RBD-region should be prioritized in booster vaccines.</p

    Clonal dynamics of SARS-CoV-2-specific T cells in children and adults with COVID-19

    No full text
    SUMMARY Children infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) develop less severe coronavirus disease 2019 (COVID-19) than adults. The mechanisms for the age-specific differences and the implications for infection-induced immunity are beginning to be uncovered. We show by longitudinal multimodal analysis that SARS-CoV-2 leaves a small footprint in the circulating T cell compartment in children with mild/asymptomatic COVID-19 compared to adult household contacts with the same disease severity who had more evidence of systemic T cell interferon activation, cytotoxicity and exhaustion. Children harbored diverse polyclonal SARS-CoV- 2-specific naïve T cells whereas adults harbored clonally expanded SARS-CoV-2-specific memory T cells. More naïve interferon-activated CD4+ T cells were recruited into the memory compartment and recovery was associated with the development of robust CD4+ memory T cell responses in adults but not children. These data suggest that rapid clearance of SARS-CoV-2 in children may compromise their cellular immunity and ability to resist reinfection. HIGHLIGHTS: Children have diverse polyclonal SARS-CoV-2-specific naïve T cells, Adults have clonally expanded exhausted SARS-CoV-2-specific memory T cells, Interferon-activated naïve T cells differentiate into memory T cells in adults but not children, Adults but not children develop robust memory T cell responses to SARS-CoV-
    corecore